New Horizon Health Limited

Equities

6606

KYG6485S1021

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 04:08:30 2024-03-27 am EDT 5-day change 1st Jan Change
14.14 HKD -19.75% Intraday chart for New Horizon Health Limited -23.07% -38.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023 CI
New Horizon Health Forecasts Up to 168% Rise in 2023 Revenue MT
New Horizon Health Limited Provides Group Earnings Guidance for the Year Ended December 31, 2023 CI
New Horizon Health Swings to Profit in H1 as Revenue Soars 265% MT
New Horizon Health Limited commences an Equity Buyback Plan for 45,759,199 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023. CI
New Horizon Health Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
New Horizon Health Rejects Short Seller's Allegations MT
New Horizon Health Forecasts Swing to Profit in H1; Shares Plunge 9% MT
New Horizon Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023 CI
New Horizon Health Plans Up to HK$500 Million Share Repurchase MT
New Horizon Health Sees Up to 271% Increase in H1 Revenue MT
New Horizon Health Limited Provides Group Earnings Guidance for the Six Months Ended June 30, 2023 CI
New Horizon Health Grants Share Options, RSUs to Various Directors, Employees MT
New Horizon Health Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
New Horizon Health Chief Scientific Officer to Sell 6.41% Stake; Shares Fall 4% MT
New Horizon Health Expects Up to 268% Boost in FY22 Revenue MT
New Horizon Health Limited Provides Group Earnings Guidance for the Year Ended December 31, 2022 CI
New Horizon Health Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
UBS Adjusts New Horizon Health's Price Target to HK$51 From HK$47, Keeps at Buy MT
New Horizon Health Limited Announces Address Changes CI
New Horizon Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022 CI
New Horizon Health Gets New Chairman in Management Shake-up MT
New Horizon Health Limited Announces Board Changes CI
New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer CI
UBS Adjusts New Horizon Health’s Price Target to HK$47 From HK$52 Keeps at Buy MT
Chart New Horizon Health Limited
More charts
New Horizon Health Limited is a China-based investment holding company principally engaged in the research and development of screening products for colorectal cancer, cervical cancer and other types of cancer. The Company distributes its ColoClear, Pupu tube and other products to customers through its own network, contracted sales organisations (CSOs) and Internet sales or e-platform operated by healthcare clinics.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.06 CNY
Average target price
32.48 CNY
Spread / Average Target
+148.69%
Consensus
  1. Stock
  2. Equities
  3. Stock New Horizon Health Limited - Hong Kong S.E.
  4. News New Horizon Health Limited
  5. New Horizon Health : Eyes $30 Million Contribution in Diagnostic Technology Fund